BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31776787)

  • 1. Leukemic Non-nodal Mantle Cell Lymphoma: Diagnosis and Treatment.
    Jain AG; Chang CC; Ahmad S; Mori S
    Curr Treat Options Oncol; 2019 Nov; 20(12):85. PubMed ID: 31776787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later.
    Fang H; Medeiros LJ; Tang Z; Wang W; Ok CY; Patel KP; Khoury JD; Thakral B
    Ann Diagn Pathol; 2021 Feb; 50():151649. PubMed ID: 33189964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathologic diagnosis of mantle cell lymphoma.
    Li S; Xu J; You MJ
    Histol Histopathol; 2021 Oct; 36(10):1037-1051. PubMed ID: 34114641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent Presentation of Hairy Cell Leukemia and Mantle Cell Lymphoma (Leukemic Non-Nodal Variant): An Extremely Rare Composite Lymphoma.
    Soliman DS; Ibrahim F; Fernyhough LJ; Murad F; Akiki S
    J Hematol; 2022 Feb; 11(1):21-28. PubMed ID: 35356636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smoldering mantle cell lymphoma.
    Ye H; Desai A; Zeng D; Nomie K; Romaguera J; Ahmed M; Wang ML
    J Exp Clin Cancer Res; 2017 Dec; 36(1):185. PubMed ID: 29246179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indolent mantle cell lymphoma.
    Hsi ED; Martin P
    Leuk Lymphoma; 2014 Apr; 55(4):761-7. PubMed ID: 23927395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage.
    Soleimani A; Navarro A; Liu D; Herman SEM; Chuang SS; Slavutsky I; Narbaitz M; Safah H; Schmieg J; Lefante J; Roschewski M; Wilson WH; Wiestner A; Saba NS
    Leuk Lymphoma; 2022 Apr; 63(4):911-917. PubMed ID: 34781807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.
    Kahl BS; Dreyling M; Gordon LI; Martin P; Quintanilla-Martinez L; Sotomayor EM
    Leuk Lymphoma; 2019 Aug; 60(8):1853-1865. PubMed ID: 30696305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profiling and management of mantle cell lymphoma.
    Ruan J
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):30-40. PubMed ID: 31808882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
    Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
    Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.
    Condoluci A; Rossi D; Zucca E; Cavalli F
    Curr Oncol Rep; 2018 Aug; 20(10):79. PubMed ID: 30132080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How I manage mantle cell lymphoma: indolent versus aggressive disease.
    Wilson MR; Barrett A; Cheah CY; Eyre TA
    Br J Haematol; 2023 Apr; 201(2):185-198. PubMed ID: 36807902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14.
    Gallo M; Cacheux V; Vincent L; Bret C; Tempier A; Guittard C; Macé A; Leventoux N; Costes V; Szablewski V
    Virchows Arch; 2016 Dec; 469(6):697-706. PubMed ID: 27605053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and/or 13q14.
    Chapman-Fredricks J; Sandoval-Sus J; Vega F; Lossos IS
    Ann Diagn Pathol; 2014 Aug; 18(4):214-9. PubMed ID: 24852242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.
    Dreyling M; Hoster E; Bea S; Hartmann E; Horn H; Hutter G; Salaverria I; Pott C; Trneny M; Le Gouill S; Cortelazzo S; Szymczyk M; Jurczak W; Shpilberg O; Ribrag V; Hermine O;
    Leuk Lymphoma; 2010 Sep; 51(9):1612-22. PubMed ID: 20629519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management.
    Isaac KM; Portell CA; Williams ME
    Curr Oncol Rep; 2021 Jul; 23(9):102. PubMed ID: 34269910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.